Tirzepatide 30mg

Tirzepatide is a novel dual incretin receptor agonist that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating these pathways, tirzepatide enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. This multifaceted mechanism has positioned it as a significant advancement in the treatment of type 2 diabetes and obesity.

Large-scale clinical trials (e.g., the SURPASS and SURMOUNT programs) have demonstrated that tirzepatide produces substantial reductions in HbA1c and body weight, often exceeding those observed with traditional GLP-1 receptor agonists. Participants have achieved significant weight loss alongside improved glycemic control and cardiometabolic markers. Common side effects are primarily gastrointestinal, including nausea and diarrhea. Ongoing research is evaluating its long-term cardiovascular outcomes and potential benefits across broader metabolic conditions.